Cortical Technology

Small molecule cytokine antagonists
3-D structure of MIF, showing Cortical MIF antagonists in purple

Inflammatory diseases can be successfully targeted with anti-cytokine therapies. Small molecule cytokine antagonists have never previously been developed, but may provide a valuable combination of effectiveness in treatment, potential oral administration, and a cost which may allow more patients to receive the treatment. In addition such molecules have the potential for formulation for use as a topical treatment or as an aerosol.

One of the most attractive targets for the development of small molecule cytokine antagonists is MIF.

(3-D structure of MIF, showing Cortical MIF antagonists in purple.)

Macrophage migration inhibitory factor
Macrophage migration inhibitory factor, or MIF, is an emerging therapeutic target in inflammatory diseases . Work from laboratories including those of Drs Morand and Iskander have determined that MIF plays an essential role in the initiation and perpetuation of the immune and inflammatory responses. Blockade of MIF by antibodies has been shown to be effective in experimental models of rheumatoid arthritis, colitis, multiple sclerosis, asthma, sepsis, and other inflammatory conditions.

MIF and corticosteroids
This information alone justifies MIF as a therapeutic target. In addition, MIF has an unique relationship with corticosteroids which are often used to treat inflammatory diseases. Unlike other pro-inflammatory cytokines, the levels of MIF are actually increased by corticosteroids. The increased levels of MIFact to antagonise or limit the effects of corticosteroids. The presence of increased MIF following corticosteroid treatment means that corticosteroids work less efficiently.

Therefore, antagonising MIF might provide a means to increase the effectiveness of corticosteroids, thus reducing the dose required to achieve a required effect. This is known as a "steroid-sparing" effect. As steroid side effects are dose dependent, steroid-sparing would be of immense value to patients.

Recent publications on macrophage migration inhibitory factor by Cortical scientists

Partnerships
Cortical is actively seeking scientific and commercial partnerships for its MIF antagonist program.  

The MIF antagonist program is at lead optimization stage, with potential to advance towards pre-clinical development compounds within one year. Partners interested in novel compounds with a clear chemistry rationale and development plan should contact Cortical via its CEO Nicole Fowler (see People). 

Cortical has a long-standing partnership with Monash University, through which R&D is done under contract. Cortical’s original founding IP was invented at Monash, and its CSO maintains an active Monash academic research group in parallel to Cortical drug discovery activities.  

Cortical enjoys a good relationship with Genzyme Corporation, which is a shareholder in Cortical but has no other connection to Cortical’s program.  

Cortical has also enjoyed strong support from Australian Federal Government, having received an NH&MRC Development Grant, Ausindustry Biotechnology Innovation Fund Grant, and Ausindustry START Grant.